Abstracts Archive

Introduction and Objectives:Patients with advanced extranodal NK/T-cell lymphoma (ENKTL) or early-stage non-upper aero-digestive tract (NUAT) involvement face a poor prognosis and frequently develop hemophagocytic lymphohistiocytosis (HLH). This prospective, single-arm, multicenter, Phase II study a...

Introduction: Mogamulizumab, a CC chemokine receptor 4 (CCR4)-targeting antibody, is approved for relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS) following ≥1 systemic therapy. In a Phase 2 trial assessing a novel 2.0 mg/kg every-4-week dosing regimen (NCT04745234), immunologic and ...

DR-01 is a non-fucosylated human IgG antibody targeting CD94, expressed on terminal effector CD8+T cells, γδT cells, and NK cells leading to depletion of CD94-expressing malignant cells by antibody-dependent cellular cytotoxicity. Patients with relapsed/refractory (R/R) cytotoxic T cell lymphomas ...

Introduction: The prognosis for patients (pts) with advanced-stage Mycosis Fungoides (MF) and Sézary syndrome (SS) is poor and better treatments are needed. Methods: This is a phase 1, 3+3 dose de-escalation study of brentuximab vedotin (BV) and mogamulizumab (Moga) in relapsed/refractory (R/R...

IntroductionCutaneous T-Cell Lymphoma (CTCL) encompasses a heterogeneous group of malignancies, including Mycosis Fungoides (MF) and Sezary Syndrome (SS). Interferon alpha (IFN-α) has been a standard treatment for CTCL since 1984; however, data on pegylated interferons remain limited. This study ai...

INTRODUCTION: BV, an ADC targeting CD30, has shown activity in lymphomas with low CD30 expression. BV+CHP was effective in patients with PTCL with CD30 ≥10%.METHODS: SGN35-032 (NCT04569032) is a phase 2 study. Patients received 21-day cycles of BV 1.8mg/kg, cyclophosphamide 750mg/m2, and doxorubi...

IntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a rare, systemic subtype of peripheral T-cell lymphoma characterized by profound immune dysregulation. Its ability to mimic infectious diseases, creates diagnostic challenges that delay treatment, particularly in tuberculosis endemic regions l...